Table 4.

SVR outcomes based on the prescribed anti-HCV medication.

Current treatment	GI clinic (noncirrhotic) Group-1 (n = 192)	PCP clinic (noncirrhotic) Group-2 (n = 185)	p value	n (%) of patients achieving SVR in GI clinic for the drug	n (%) of patients achieving SVR in PCP clinic for the drug
Harvoni	123 (64.06)	144 (77.84)	<0.01	120 (97.56)	134 (93.06)
Sofosbuvir+ribavirin	33 (17.19)	0		32 (96.97)	0
Epclusa	0	25 (13.51)		0	24 (96.00)
Viekira+ribavirin	17 (8.85)	0		15 (88.24)	0
Zepatier	0	15 (8.11)		0	14 (93.33)
Harvoni+ribavirin	9 (4.69)	1 (0.54)		7 (77.78)	1 (100)
Sofosbuvir+Harvoni	3 (1.56)	0		3 (100)	0
Sofosbuvir+simeprevir	1 (0.52)	0		1 (100)	0
Daklinza+sofosbuvir	1 (0.52)	0		1 (100)	0
Sofosbuvir+ribavirin+IFN	1 (0.52)	0		1 (100)	0
Ledipasvir/sofosbuvir	1 (0.52)	0		1 (100)	0
Viekira	1 (0.52)	0		1 (100)	0
Technivie/ribavirin	1 (0.52)	0		1 (100)	0
Harvoni/Viekira/Zepatier	1 (0.52)	0		1 (100)	0

Abbreviations: GI: gastroenterology; PCP: primary care physician; SVR: sustained virological response; IFN: interferon.